mCSPC
mCSPC
Advertisement
David Morris, MD, FACSmHSPC | December 12, 2024
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
View More
David Morris, MD, FACSmHSPC | December 12, 2024
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
David Morris, MD, FACSmHSPC | December 12, 2024
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
David Morris, MD, FACSCRPC | December 12, 2024
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
David Morris, MD, FACSmHSPC | December 12, 2024
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
David Morris, MD, FACSCRPC | December 12, 2024
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
Irbaz B. Riaz, MBBS, PhDProstate Cancer Diagnostics | November 5, 2024
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Irbaz B. Riaz, MBBS, PhDmHSPC | November 5, 2024
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Irbaz B. Riaz, MBBS, PhDmHSPC | November 5, 2024
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Irbaz B. Riaz, MBBS, PhDProstate Cancer Diagnostics | November 5, 2024
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
Marc Greenstein, DOmCSPC | October 31, 2024
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Leonard J. Appleman, MD, PhDmCSPC | October 29, 2024
Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials.
Leonard J. Appleman, MD, PhDmCSPC | October 25, 2024
Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy.
Leonard J. Appleman, MD, PhDProstate Cancer Diagnostics | October 24, 2024
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Leonard J. Appleman, MD, PhDProstate Cancer Diagnostics | October 24, 2024
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
Pedro Barata, MDmCSPC | October 2, 2024
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
Pedro Barata, MDmCSPC | October 2, 2024
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
Andrew Laccetti, MD, MSmCSPC | September 25, 2024
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Samantha Armstrong, MDMuscle Invasive Urothelial Carcinoma | October 1, 2024
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
Christopher Wallis, MD, PhD, FRCSCCRPC | October 1, 2024
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
Advertisement
Advertisement
Advertisement